Role of Glycolytic and Glutamine Metabolism Reprogramming on the Proliferation, Invasion, and Apoptosis Resistance through Modulation of Signaling Pathways in Glioblastoma
Por:
Trejo-Solis, C, Silva-Adaya, D, Serrano-Garcia, N, Magana-Maldonado, R, Jimenez-Farfan, D, Ferreira-Guerrero, E, Cruz-Salgado, A, Castillo-Rodriguez, RA, Laezza, C
Publicada:
1 dic 2023
Resumen:
Simple Summary Metabolic reprogramming in glioblastoma is a hallmark of malignancy. Metabolic enzymes and metabolites participate in energetic metabolism and function as signaling molecules associated with genomic instability, mutations, epigenetic changes, and the activation of oncogenic signaling pathways. In addition, metabolites obtained from the metabolic network regulate several metabolic enzymes facilitating malignancy, therapeutic resistance, and tumor recurrence at the transcriptional and post-translational levels. In this review, we described the role of the glycolytic and glutamine metabolic network as an inductor of the cellular pathophysiology of glioblastoma as well as a therapeutic target in glioma cells.Abstract Glioma cells exhibit genetic and metabolic alterations that affect the deregulation of several cellular signal transduction pathways, including those related to glucose metabolism. Moreover, oncogenic signaling pathways induce the expression of metabolic genes, increasing the metabolic enzyme activities and thus the critical biosynthetic pathways to generate nucleotides, amino acids, and fatty acids, which provide energy and metabolic intermediates that are essential to accomplish the biosynthetic needs of glioma cells. In this review, we aim to explore how dysregulated metabolic enzymes and their metabolites from primary metabolism pathways in glioblastoma (GBM) such as glycolysis and glutaminolysis modulate anabolic and catabolic metabolic pathways as well as pro-oncogenic signaling and contribute to the formation, survival, growth, and malignancy of glioma cells. Also, we discuss promising therapeutic strategies by targeting the key players in metabolic regulation. Therefore, the knowledge of metabolic reprogramming is necessary to fully understand the biology of malignant gliomas to improve patient survival significantly.
Filiaciones:
Trejo-Solis, C:
Inst Nacl Neurol & Neurocirug, Lab Expt Enfermedades Neurodegenerat, Lab Reprogramac Celular, Dept Neurofisiol, Ciudad De Mexico 14269, Mexico
Silva-Adaya, D:
Inst Nacl Neurol & Neurocirug, Lab Expt Enfermedades Neurodegenerat, Lab Reprogramac Celular, Dept Neurofisiol, Ciudad De Mexico 14269, Mexico
Serrano-Garcia, N:
Inst Nacl Neurol & Neurocirug, Lab Expt Enfermedades Neurodegenerat, Lab Reprogramac Celular, Dept Neurofisiol, Ciudad De Mexico 14269, Mexico
Magana-Maldonado, R:
Inst Nacl Neurol & Neurocirug, Lab Expt Enfermedades Neurodegenerat, Lab Reprogramac Celular, Dept Neurofisiol, Ciudad De Mexico 14269, Mexico
Jimenez-Farfan, D:
Univ Nacl Autonoma Mexico, Fac Odontol, Div Estudios Posgrad & Invest, Lab Inmunol, Ciudad De Mexico 04510, Mexico
Ferreira-Guerrero, E:
Inst Nacl Salud Publ, Ctr Invest Enfermedades Infecciosas, Cuernavaca 62100, Mexico
Cruz-Salgado, A:
Inst Nacl Salud Publ, Ctr Invest Enfermedades Infecciosas, Cuernavaca 62100, Mexico
Castillo-Rodriguez, RA:
Inst Politecn Nacl, CICATA Unidad Morelos, Blvd Tecnol,1036 Z-1,P 2-2, Atlacholoaya 62790, Mexico
gold, All Open Access; Gold
|